Given persistently high prices for medicines, one pharmaceutical executive is trying a gambit in hopes of widening access in lesser-developed countries and, eventually, the US. Ann Kwong, who once headed the hepatitis C franchise at Vertex Pharmaceuticals, recently assembled a team and the financial backing to open Trek Therapeutics, a public benefit corporation. The idea is to mix the traditional goal of making a profit with a large dose of altruism. Her plan is to develop new hepatitis C treatments and provide them at low cost. Trek is still very much in the early stages, but Kwong is adamant her plan can work. This is an edited version of our conversation …

Pharmalot: So before we discuss Trek, tell me about your time at Vertex.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • considering how long it takes to get a new drug approved, and how quickly HEP C patients are being cured by GILD, ABBV, MRK, etc drugs, it seems like a waste of resources.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.